Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sovaldi and trelagliptin in latest Japanese approvals

This article was originally published in Scrip

Executive Summary

Japan has approved a batch of new drugs including Gilead's Sovaldi as part of the first all-oral therapy for HCV genotype 2 in the country, Eisai's Lenvima for thyroid cancer, and the world's first once-weekly DPP-4 inhibitor from Takeda.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC028256

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel